Dimethylformamide → 2-{4-[4,5-bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-N-methyl-acetamide

HRID 31515

Reaktionsgleichung

Reaktionsgleichung von HRID 31515
ClC[C:3]([N:5]([CH3:7])[CH3:6])=[O:4].[Cl:8][C:9]1[CH:14]=[CH:13][C:12]([CH:15]2[CH:19]([C:20]3[CH:25]=[CH:24][C:23]([Cl:26])=[CH:22][CH:21]=3)[NH:18][C:17]([C:27]3[CH:32]=[CH:31][C:30]([C:33]([F:36])([F:35])[F:34])=[CH:29][C:28]=3[O:37][CH2:38][CH3:39])=[N:16]2)=[CH:11][CH:10]=1.[CH:40]([N:43]([CH:46](C)C)[CH2:44]C)(C)C.[CH3:49][N:50](C)[CH:51]=[O:52]>C(Cl)Cl.O>[Cl:8][C:9]1[CH:10]=[CH:11][C:12]([CH:15]2[CH:19]([C:20]3[CH:21]=[CH:22][C:23]([Cl:26])=[CH:24][CH:25]=3)[N:18]([C:3]([N:5]3[CH2:6][CH2:44][N:43]([CH2:46][C:51]([NH:50][CH3:49])=[O:52])[CH2:40][CH2:7]3)=[O:4])[C:17]([C:27]3[CH:32]=[CH:31][C:30]([C:33]([F:34])([F:35])[F:36])=[CH:29][C:28]=3[O:37][CH2:38][CH3:39])=[N:16]2)=[CH:13][CH:14]=1

Komponenten

7

Edukt 4

HCID 6228Dimethylformamide2×HCID 758862-chloro-N,N-dimethylacetamideHCID 81531DiisopropylethylamineHCID 101741684,5-bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-1H-imidazole

Produkt 1

HCID 112159852-{4-[4,5-bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-N-methyl-acetamide

Reagenzien, Katalysatoren, Lösungsmittel 2

HCID 962WaterLösungsmittelHCID 6344DichloromethaneLösungsmittel

Reaktionsbedingungen

Temperatur
65 °C

Versuchsvorschrift

2-Chloro-N,N-dimethyl-acetamide (0.0194 mmol) in dimethylformamide (0.25 mL) was pipeted into a 4 mL vial containing a solution of 4,5-bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-1H-imidazole (0.0169 mmol, example 1) and diisopropylethylamine (0.0194 mmol) in 0.25 mL of dimethylformamide. The vial was capped and heated to 65° C. for 2 d. The reaction was diluted with 1.5 mL of methylene chloride and 0.5 mL of water. The vial was agitated and centrifuged. The organic layer was transferred to a 4 mL vial and concentrated in vacuo to give 2-{4-[4,5-bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-N-methyl-acetamide. LR-MS: 663 [(M+H)+].

Aufarbeitung

  1. customThe vial was capped
  2. concentrationconcentrated in vacuo

Quellen und Nachweise

ORD-Eintrag
ord-6f86b4070d744a36ba17e54f5766a229
Quelldatensatz
uspto-grants-2008_09
Patentnummer
US07425638B2

Verknüpfte Notizen

Wird geladen…